These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 27886041

  • 1. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G, Strateva T, Miteva D, Lazova S, Perenovska P.
    J Infect Dev Ctries; 2016 Nov 24; 10(11):1265-1267. PubMed ID: 27886041
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec 24; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 3. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
    Moore JE, Maeda Y, Goldsmith CE, Rendall JC, Elborn JS.
    J Cyst Fibros; 2010 May 24; 9(3):237-8. PubMed ID: 20378421
    [No Abstract] [Full Text] [Related]

  • 4. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S, Waters V, Mathew JL, Taylor L, Ratjen F.
    J Cyst Fibros; 2014 Mar 24; 13(2):172-8. PubMed ID: 24091166
    [Abstract] [Full Text] [Related]

  • 5. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL.
    J Infect Dis; 1999 May 24; 179(5):1190-6. PubMed ID: 10191222
    [Abstract] [Full Text] [Related]

  • 6. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.
    N Engl J Med; 1999 Jan 07; 340(1):23-30. PubMed ID: 9878641
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R, Minicucci L.
    Int J Antimicrob Agents; 2005 Mar 07; 25(3):193-7. PubMed ID: 15737511
    [Abstract] [Full Text] [Related]

  • 8. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media.
    Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK.
    J Antimicrob Chemother; 2008 May 07; 61(5):1057-61. PubMed ID: 18316821
    [Abstract] [Full Text] [Related]

  • 9. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC, Rendall JC, Downey DG, Moore JE.
    J Clin Pharm Ther; 2018 Dec 07; 43(6):836-843. PubMed ID: 29959786
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL.
    Chest; 2003 May 07; 123(5):1495-502. PubMed ID: 12740266
    [Abstract] [Full Text] [Related]

  • 11. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F.
    Rev Med Liege; 2013 Sep 07; 68(9):486-8. PubMed ID: 24180205
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.
    J Control Release; 2015 Jan 28; 198():55-61. PubMed ID: 25481442
    [Abstract] [Full Text] [Related]

  • 13. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB.
    J Antimicrob Chemother; 2011 Oct 28; 66(10):2398-404. PubMed ID: 21784781
    [Abstract] [Full Text] [Related]

  • 14. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G, Radike K, Schoen C, Horn S, Oesterlein A, Frosch M, Abele-Horn M, Hebestreit H.
    Scand J Infect Dis; 2010 Dec 28; 42(11-12):885-9. PubMed ID: 20735333
    [Abstract] [Full Text] [Related]

  • 15. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
    Griese M, Müller I, Reinhardt D.
    Eur J Med Res; 2002 Feb 21; 7(2):79-80. PubMed ID: 11891148
    [Abstract] [Full Text] [Related]

  • 16. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S, McKay K, Vidmar S, O'Brien K, Stacey S, Cheney J, Wainwright CE.
    J Cyst Fibros; 2014 Jul 21; 13(4):428-34. PubMed ID: 24565869
    [Abstract] [Full Text] [Related]

  • 17. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Møller NE, Høiby N.
    Scand J Infect Dis Suppl; 1981 Jul 21; 29():87-91. PubMed ID: 6458884
    [Abstract] [Full Text] [Related]

  • 18. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N, Yalcin E, Meral A, Sener B, Dogru D, Ozcelik U, Kiper N.
    J Clin Pharm Ther; 2016 Aug 21; 41(4):419-23. PubMed ID: 27311742
    [Abstract] [Full Text] [Related]

  • 19. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index.
    Milne KE, Gould IM.
    J Antimicrob Chemother; 2010 Jan 21; 65(1):82-90. PubMed ID: 19861334
    [Abstract] [Full Text] [Related]

  • 20. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Li Y, Zhang X, Wang C, Hu Y, Niu X, Pei D, He Z, Bi Y.
    Mol Med Rep; 2015 Jan 21; 11(1):494-8. PubMed ID: 25323940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.